Bristol-Myers Squibb Company

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.

USANewsGroup.com News Commentary

VANCOUVER, BC, May 12, 2026 /CNW/ -- Cardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in late April: U.S. heart disease costs are on pace to quadruple by 2050, and total national healthcare spending is already closing in on $5 trillion a year^[1]. That kind of structural pressure is forcing hospitals to rethink how they diagnose and treat cardiac patients, and the money is following. The global AI cardiology market, valued at $2.78 billion this year, is projected to reach over $14 billion by 2034 as health systems race to deploy machine learning tools that can cut through diagnostic backlogs^[2]. Five companies sit at the center of this convergence: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), BridgeBio Pharma (NASDAQ: BBIO), Bristol Myers Squibb (NYSE: BMY), Arrowhead Pharmaceuticals (NASDAQ: ARWR), and Amgen (NASDAQ: AMGN).

The investment case gets sharper when you look at the device side. Analysts project the interventional cardiology devices market will climb from $31.12 billion to $42.39 billion by 2031, driven by minimally invasive procedures and AI-powered imaging that keep expanding the treatable patient pool^[3]. Meanwhile, the wearable ECG monitoring sector has hit $5.9 billion and is growing at a 23.4% annual clip, confirming that portable, AI-driven cardiac diagnostics have become the primary value driver pulling institutional capital into this space^[4].

VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is heading to Europe next week to showcase its AI-powered cardiac imaging platform at one of the biggest cardiology conferences on the planet. The company will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), running May 12 to 16 in Padua, Italy, alongside European distributor AngioPro. AEPC is the world's largest association in congenital cardiology, with over 1,000 specialists across 32 countries, and this year's program is centered on cardiovascular imaging and artificial intelligence, exactly the areas where VentriPoint operates.

VMS+™ 4.0 takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to cardiac MRI, but without the million-dollar machine or the months-long wait list. Built on more than a decade of proprietary Knowledge Based Reconstruction technology, the system works with ultrasound equipment from any manufacturer and holds regulatory approvals in the United States, Canada, and Europe.

That regulatory footprint is expanding. In late April, VentriPoint announced that strategic partner Lishman Global Inc. formally submitted VMS+™ 4.0 to China's National Medical Products Administration (NMPA) for approval. Lishman Global qualified for the NMPA's expedited "green channel" review pathway, reserved for innovative technologies addressing significant clinical needs. China has an estimated 330 million patients affected by cardiovascular disease.

Commercial momentum has been building. VentriPoint recently picked up a Gold Medal at the 2026 Edison Awards for VMS+™ 4.0. It announced a collaboration with the Health Division of the Montecristo Group to deploy VMS+™ across Costa Rica's hospital networks, where Hospital Metropolitano has an existing relationship with Sanford Health. VentriPoint also recently partnered with First Light Health to bring cardiac diagnostics to Indigenous and remote communities across Canada, building on an earlier partnership with the Nisga'a Valley Health Authority. The company also signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California.

"AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," said Hugh MacNaught, President and CEO of VentriPoint. "VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI, giving clinicians the confidence they need to manage their patients at every stage of life."

With regulatory submissions advancing in China, distribution partners spanning Costa Rica to Northern California, Edison Award recognition, and a growing presence at major cardiology conferences, VentriPoint is building the kind of global footprint that turns a promising medtech platform into a scalable business.

CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint.

Other industry developments and happenings in the market include:

BridgeBio Pharma (NASDAQ: BBIO) presented long-term efficacy data from the ATTRibute-CM open-label extension trial at the American College of Cardiology Annual Scientific Sessions, showing acoramidis reduced all-cause mortality risk by 44.7% and cardiovascular mortality risk by 49.3% versus placebo-to-acoramidis through Month 54 (p<0.0001 for both). The data, simultaneously published in JAMA Cardiology, represent the earliest timepoint in an open-label extension with this magnitude of risk reduction, and acoramidis continued to be well tolerated with no long-term safety concerns.

"The ATTRibute-CM long-term data show that early and continuous treatment with acoramidis can meaningfully change the trajectory of this disease, with sustained reductions in all-cause and cardiovascular mortality, cardiovascular hospitalization, continued mitigation of NT-proBNP progression, and a favorable long-term safety profile," said Dr. Prem Soman, University of Pittsburgh School of Medicine. "These findings reinforce the importance of early diagnosis followed by prompt, durable treatment to deliver sustained clinical benefit for patients."

Acoramidis is approved as Attruby by the U.S. FDA and as BEYONTTRA by the European Medicines Agency, with both labels specifying near-complete stabilization of TTR. BridgeBio Pharma also noted that additional Attruby data are planned for future medical meetings.

Bristol Myers Squibb (NYSE: BMY) reported positive Phase 3 results from its SCOUT-HCM trial evaluating Camzyos (mavacamten) in adolescents aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The trial met its primary endpoint, showing a statistically significant reduction in Valsalva left ventricular outflow tract gradient at Week 28, with a least-squares mean difference of -48.0 mm Hg versus placebo (P < 0.0001), and no patients experienced left ventricular ejection fraction below 50%.

"The SCOUT-HCM results underscore the potential for Camzyos to become the first CMI for adolescents, reinforcing our leadership in the CMI space and our role in reshaping the scientific understanding of oHCM and how the disease is diagnosed, evaluated and potentially treated," said Cristian Massacesi, MD, executive vice president, Chief Medical Officer and Head of Development, Bristol Myers Squibb. "With these meaningful safety and efficacy data, we are excited about the potential to provide a paradigm-changing treatment for adolescents and their families."

Camzyos is already approved in more than 60 countries for adult oHCM and has been prescribed to over 22,000 patients in the U.S., positioning Bristol Myers Squibb to potentially expand its label into a pediatric population with no currently approved targeted therapies.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented long-term clinical data for plozasiran at the American College of Cardiology's 75th Annual Scientific Session, showing patients with severe hypertriglyceridemia achieved an 83% median reduction in triglycerides over two years, with 96% reaching levels below 500 mg/dL, the threshold associated with acute pancreatitis risk. No adjudicated acute pancreatitis events occurred in any patient receiving plozasiran during the two-year Phase 2b open-label extension study, and favorable reductions in atherogenic lipoproteins were observed with a consistent safety profile.

"We're pleased with the consistent, positive clinical results we're seeing with plozasiran across the spectrum of hypertriglyceridemias and we're excited about what this could mean for patients," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. "In the four months since its FDA approval for treating FCS, plozasiran is already making a meaningful difference for the FCS community, and we believe it has the potential to become an important therapy for people living with severe hypertriglyceridemia as well."

Arrowhead Pharmaceuticals expects to complete its SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 studies by mid-2026 and intends to submit a supplemental New Drug Application to the FDA by year-end 2026, targeting broader marketing approval for plozasiran across the hypertriglyceridemia spectrum.

Amgen (NASDAQ: AMGN) reported that its Repatha® (evolocumab) reduced the risk of first major adverse cardiovascular events by 31% in high-risk primary prevention patients with diabetes but without known significant atherosclerosis. The findings, from a subgroup analysis of 3,655 patients in the Phase 3 VESALIUS-CV trial followed over a median 4.8 years, showed consistent 31% reductions across both 3-P MACE and 4-P MACE composite endpoints, with a median achieved LDL-C of 44 mg/dL in the Repatha arm.

"The evidence is unequivocal: Intensive LDL-C lowering with Repatha significantly reduces the risk of major CV events for high-risk patients," said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. "These data also show the benefit of lowering LDL-C below 45 mg/dL with Repatha, a level that may not be achieved with statins or ezetimibe alone."

Repatha is the only PCSK9 inhibitor to demonstrate significant cardiovascular event reduction in both high-risk primary and secondary prevention settings and has been prescribed to more than 8 million patients globally across 74 countries. The U.S. Food and Drug Administration expanded Repatha's approved use in August 2025 to include adults at increased risk for major adverse CV events due to uncontrolled LDL-C.

Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint

CONTACT:

USA NEWS GROUP

info@usanewsgroup.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES:

1. https://newsroom.heart.org/news/health-care-costs-reach-a-breaking-point 
2. https://www.fortunebusinessinsights.com/ai-in-cardiology-market-115767 
3. https://www.reportsnreports.com/healthcare/medical-devices-reports/interventional-cardiology-devices-market-to-reach-42-39-billion-by-2031-at-a-cagr-of-6-4/ 
4. https://www.globenewswire.com/news-release/2026/04/13/3272639/0/en/Wearable-ECG-Monitors-Industry-to-More-Than-Double-During-2026-2030-Exceeding-13-6-Billion-Total-Revenue-Rising-Demand-for-AI-Driven-Diagnostics-and-Home-Based-Cardiac-Monitoring.html

Logo: https://mma.prnewswire.com/media/2838876/5965420/USA_News_Group_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/wall-streets-cardiac-bet-where-diagnostics-meet-the-money-302769483.html

SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.

"This milestone marks a meaningful step forward for Atrium, further expanding our RNA delivery platform and our ability to generate high quality cardiology development candidates," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. "The successful advancement of this first development candidate reflects the strength of our science, the productivity of our collaboration with Bristol Myers Squibb, and our shared commitment to deliver transformative therapies for patients with cardiac disease."

The payment is pursuant to Atrium's global licensing and research collaboration with Bristol Myers Squibb focused on the discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications.

Under the terms of the agreement, Atrium is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from the collaboration.

About Atrium Therapeutics

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from delivery to the skeletal muscle and applies it for efficient delivery to the heart with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.

For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

Availability of Other Information About Atrium Therapeutics

Investors and others should note that Atrium Therapeutics communicates with its investors and the public using its website https://atriumtherapeutics.com/, including, but not limited to, Atrium Therapeutics' disclosures, investor presentations and FAQs, Securities and Exchange Commission ("SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Atrium Therapeutics posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Atrium Therapeutics encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Atrium Therapeutics' website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

About PRKAG2 Syndrome

PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in heart muscle cells leading to thickened heart muscles, electrical conduction problems, and arrhythmias. There are 1,000 – 2,000 people with PRKAG2 syndrome in the US. Current management is limited to symptomatic treatment; no approved therapies exist to address the underlying genetic driver of disease.

About PLN Cardiomyopathy

PLN (phospholamban) cardiomyopathy is a rare autosomal dominant, progressive cardiac disease caused by mutations in PLN, a key regulator of SERCA2a calcium pump. PLN mutations produce protein aggregates that disrupt endoplasmic reticulum processes and lead to dilated, arrhythmogenic, or hypertrophic cardiomyopathies and a significantly increased risk of heart failure and sudden cardiac death. There are 2,000 – 4,000 people with pathogenic PLN variants in the US. No approved therapies target the underlying molecular cause of the disease.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding Atrium Therapeutics' ("Atrium's" or "our") future results of operations and financial condition; research and development plans; anticipated timing, design and conduct of ongoing and planned preclinical studies and clinical trials for product candidates; our expectations regarding our RNA delivery platform and ability to generate high quality cardiology development candidates, the timing and likelihood of regulatory filings and approvals for product candidates; the potential safety and therapeutic benefits of our product candidates; the timing and likelihood of success; plans and objectives of management for future operations; and future results of anticipated product development efforts. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Particular areas where risks or uncertainties could cause Atrium's actual results to be materially different than those expressed in Atrium's forward-looking statements include but are not limited to: the initiation, timing, progress, potential registrational quality, and results of our research and development programs, preclinical studies, any clinical trials, and other regulatory submissions; the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our product candidates and the potential advantages of our product candidates compared to alternative therapies; the success and capabilities of the RNA delivery platform; the prevalence of certain diseases and conditions we intend to treat and our estimates of the potential market opportunity for our product candidates; the timing of and costs involved in obtaining and maintaining regulatory approval of our current and any future product candidates; our ability to develop our current and future product candidates; the implementation of our strategic plans for our business, product candidates, research programs and technologies; developments related to our competitors and our industry; our competitive position and the success of competing therapies that are or may become available; our ability to maintain our current license agreements and collaborations and identify and enter into future license agreements and collaborations; the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators in the future; our reliance on third parties for manufacturing and to conduct preclinical studies and clinical trials of our product candidates; our ability to efficiently and cost-effectively conduct our current and future clinical trials; the costs of operating as a public company; the accuracy of our estimates regarding future expenses, future revenue, capital requirements and the need for additional financing; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and other factors specified in Atrium's Registration Statement on Form 10, initially publicly filed by Atrium with the Securities and Exchange Commission (the "SEC") on December 10, 2025 and in other filings and furnishings made by Atrium with the SEC from time to time. Atrium is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except as required by law.

Investor and Media Contact:

Stephanie Kenney, Chief Corporate Affairs Officer, investors@atrium-tx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/atrium-therapeutics-earns-15-million-milestone-payment-from-bristol-myers-squibb-under-global-cardiovascular-collaboration-302751102.html

SOURCE Atrium Therapeutics